{
  "docId": "019dd923-622c-750b-8b97-e9d223c0ba42",
  "docSlug": "88a4417a0cf1",
  "documentTitle": "Apellis Pharmaceuticals (APLS)",
  "authorId": "52_Citron_Research",
  "authorName": "Citron Research",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-11-06 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77295077,
  "pageNumber": 2,
  "pageCount": 13,
  "prevPage": 1,
  "nextPage": 3,
  "slideType": "research-note",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a 'jumped the shark' idiom to frame the drug's clinical reception as having peaked and begun a decline in credibility.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "screenshot",
    "callout_box"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b97-e9d223c0ba42/2",
  "deckHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b97-e9d223c0ba42#slide-2",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Friday, November 3, 2023 is the day Syfovre \"Jumped the Shark\"",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-1ac1-76e9-bcd7-eb1c41edf16d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.39,
        "x": 0.305,
        "y": 0.258
      },
      "kind": "image",
      "text": "AAO 2023 logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ea71042-4fb5-484a-ab55-5a385a02df8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.2,
        "y": 0.535
      },
      "kind": "image",
      "text": "Current Complement Inhibition Therapy for Geographic Atrophy Is Acceptable: 1. Pro (Usha Chakravarthy PhD MBBS) 2. Con (Richard F Spaide MD)",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9c8be4b-cb65-4b7a-89b8-a338935b71c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.77,
        "x": 0.118,
        "y": 0.403
      },
      "kind": "paragraph",
      "text": "This past Friday was the first meeting of the AAO since the approval of Syfovre, there was a panel debate on Syfovre, questioning whether the treatment is \"acceptable\".",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a6411ca-1ae2-47ba-99d1-3289d03e1460",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.77,
        "x": 0.118,
        "y": 0.738
      },
      "kind": "paragraph",
      "text": "The PRO - Dr. Chakravarthy, a respected academic, described the new treatment as a progressive development in the quest for effective therapies. She emphasized the ongoing necessity for innovation and investment in addressing the disease.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ae4390d-fa2e-4ce7-9016-18b2c80ecacc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.77,
        "x": 0.118,
        "y": 0.163
      },
      "kind": "paragraph",
      "text": "Last week was the first meeting of the American Academy of Ophthalmology in San Francisco since the approval of Syfovre. The Academy has the world's largest association of eye physicians and surgeons with more than 32,000 doctors.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7c397fc-ac5f-4fac-9a10-475973be20b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.118,
        "y": 0.353
      },
      "kind": "title",
      "text": "Friday, November 3, 2023 is the day Syfovre \"Jumped the Shark\"",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af08eb0c-e01d-48c0-8056-2382eab79cf2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.118,
        "y": 0.113
      },
      "kind": "title",
      "text": "Everything Has Now Changed!!",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b792b1f2-21f0-4e14-93e8-3a4fc1ea84e3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 2,
      "beatId": "35b7911a-b113-4112-9253-57c0fd4ab885",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Monster",
      "beatSlug": "overcoming-monster-the-monster",
      "evidence": "The document presents Syfovre's complications as the central problem to be addressed.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1b08b18b-190c-48b4-b339-4e33de995cac",
      "evidence": "The document implies that failure to address Syfovre's complications could lead to regulatory action and reputational damage.",
      "position": 1,
      "objective": "What are the consequences of not taking action against Syfovre's safety concerns?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}